High specific immune response to a bivalent anti-HPV vaccine in HIV-1-infected men in Sao Paulo, Brazil

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author FONTES, Adriele FMUSP-HC
ANDREOLI, Maria Antonieta
VILLA, Luisa Lina FMUSP-HC
ASSONE, Tatiane FMUSP-HC
GAESTER, Karen FMUSP-HC
FONSECA, Luiz A. M. FMUSP-HC
DUARTE, Alberto J. S. FMUSP-HC
CASSEB, Jorge FMUSP-HC
dc.date.issued 2016
dc.identifier.citation PAPILLOMAVIRUS RESEARCH, v.2, p.17-20, 2016
dc.identifier.issn 2405-8521
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/20013
dc.description.abstract Introduction: Infection with Human papillomavirus (HPV) has been reported as one of the most prevalent agent sexually transmitted diseases, but its true prevalence in men is not precisely known, mainly due to the near absence of symptoms. Moreover, few studies evaluating the post-vaccination immune response have been performed to date in men, hence the hypotheses tested in this study can be important to enable a better understanding of both the immunopathogenesis and the response to vaccination in HIV-infected patients, and to help in the elaboration of strategies of vaccination against HPV in the HIV-infected population. Objectives: To analyze the specific response to antigens of HPV vaccine in HIV-infected men. Methods: A total of 25 HIV-infected male patients who met the inclusion criteria during the data collection period were vaccinated; however, six (30%) had anti-HPV at baseline, and were not considered further in the analysis. Therefore, 19 HIV-infected individuals were included in the study, along with five healthy, HPV-seronegative controls. Results: Patients infected with HIV-1 were subdivided into two groups, A and B, according to their T CD4 cells count at the time of vaccination, namely: Group A: CD4 > 500; Group B: CD4 < 500. The proportion of seroconversion after immunization with three doses of a bivalent anti-HPV vaccine was 92%. Conclusion: HIV-infected patients as well as HIV negative controls responded to anti-HPV vaccination, regardless of their T CD4 cells count and HIV plasma viral load. These results demonstrate that anti-HPV immunization in HIV-infected males is effective and should be encouraged, thus helping to decrease the risk of infection, mortality and morbidity of diseases associated with HPV in men. (C) 2016 The Authors.
dc.description.sponsorship · FAPESP [2010/07076-4, 2008/05889-1]
· CNPq [573799/2008-3]
dc.language.iso eng
dc.publisher ELSEVIER SCIENCE BV
dc.relation.ispartof Papillomavirus Research
dc.rights restrictedAccess
dc.subject HIV-1; HPV; Vaccine; Immune response
dc.subject.other human-papillomavirus infection; intraepithelial neoplasia; young-women; hiv; immunogenicity; safety; efficacy; cancer; impact
dc.title High specific immune response to a bivalent anti-HPV vaccine in HIV-1-infected men in Sao Paulo, Brazil
dc.type article
dc.rights.holder Copyright ELSEVIER SCIENCE BV
dc.description.group LIM/56
dc.description.group LIM/38
dc.description.group LIM/24
dc.identifier.doi 10.1016/j.pvr.2016.01.001
dc.type.category original article
dc.type.version publishedVersion
hcfmusp.author FONTES, Adriele:IMT:
hcfmusp.author VILLA, Luisa Lina:FM:MDR
hcfmusp.author ASSONE, Tatiane:IMT:
hcfmusp.author GAESTER, Karen:IMT:
hcfmusp.author FONSECA, Luiz A. M.:HC:ICHC
hcfmusp.author DUARTE, Alberto J. S.:FM:MPT
hcfmusp.author CASSEB, Jorge:IMT:IMT
hcfmusp.author.external · ANDREOLI, Maria Antonieta:Santa Casa Sao Paulo, HPV Inst, Sao Paulo, Brazil
hcfmusp.origem.id 2-s2.0-84999009598
hcfmusp.origem.id WOS:000399038100004
hcfmusp.publisher.city AMSTERDAM
hcfmusp.publisher.country NETHERLANDS
hcfmusp.relation.reference · Bernard HU, 2006, INT J CANCER, V118, P1071, DOI 10.1002/ijc.21655
· Betiol J, 2013, BRAZ J MED BIOL RES, V46, P217, DOI 10.1590/1414-431X20132703
· Castellsague X., 2015, VACCINE
· Ciavarra G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017682
· Denny L, 2013, VACCINE, V31, P5745, DOI 10.1016/j.vaccine.2013.09.032
· Ferguson M, 2006, INT J CANCER, V118, P1508, DOI 10.1002/ijc.21515
· Figliuolo G, 2012, INT BRAZ J UROL, V38, P411, DOI 10.1590/S1677-55382012000300015
· Gaester K, 2014, SCI REP-UK, V4, DOI 10.1038/srep06592
· Giuliano AR, 2011, NEW ENGL J MED, V364, P401, DOI 10.1056/NEJMoa0909537
· Hoots BE, 2009, INT J CANCER, V124, P2375, DOI 10.1002/ijc.24215
· Kreuter A, 2008, J INVEST DERMATOL, V128, P2316, DOI 10.1038/jid.2008.72
· Levin MJ, 2010, JAIDS-J ACQ IMM DEF, V55, P197, DOI 10.1097/QAI.0b013e3181de8d26
· Michels KB, 2009, LANCET, V374, P268, DOI 10.1016/S0140-6736(09)61247-2
· Munoz N, 2010, JNCI-J NATL CANCER I, V102, P325, DOI 10.1093/jnci/djp534
· Palefsky JM, 2011, NEW ENGL J MED, V365, P1576, DOI 10.1056/NEJMoa1010971
· Schiller JT, 2012, CURR HIV-AIDS REP, V10, P681, DOI 10.1038/NRMICR02872
· Stanley Margaret, 2010, Infect Agent Cancer, V5, P19, DOI 10.1186/1750-9378-5-19
· Toft L, 2014, SEX HEALTH, V11, P511, DOI 10.1071/SH14015
· Veiga APR, 2006, VACCINE, V24, P7124, DOI 10.1016/j.vaccine.2006.06.079
· Villa LL, 2005, LANCET ONCOL, V6, P271, DOI 10.1016/S1470-2045(05)70101-7
· Wilkin T, 2010, J INFECT DIS, V202, P1246, DOI 10.1086/656320
· zur Hausen H, 1981, Gynecol Oncol, V12, pS124, DOI 10.1016/0090-8258(81)90067-6
dc.description.index PubMed
hcfmusp.citation.scopus 2
hcfmusp.citation.wos 1
hcfmusp.affiliation.country Brasil


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace



Browse

My Account

Statistics